Correct consolidated financial reports from 2023Q1 to Q4, independent 2024Q4 financial report, and iXBRL, which have no impact on income and losses and net assets.

1.Date of occurrence of the event:2024/05/10
2.Company name: OBI Pharma, Inc.
3.Relationship to the Company (please enter ”head
office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios: N/A
5.Cause of occurrence: Pursuant to letter No. 11300023721 from Taipei Exchange,
the Company’s Board resolved to correct financial reports for 2023 each
quarter.
6.Information items/ statements to be corrected:
Correct consolidated financial reports from 2023Q1 to 2023Q4, independent
2024Q4 financial report, and the information on iXBRL website, including (1)
the amount of other receivables and other payables of Balance sheets and
statements of cash flows (2)Notes regarding other payables, expenses by
nature, employee benefit expense, related party transaction, etc.
Correction has no impact on the income and losses and net assets.
7.Amounts/ contents/ number of page to be corrected:
Correct consolidated financial reports from 2023Q1 to 2023Q4, independent
2024Q4 financial report, and the information on iXBRL website. Due to the
large number of corrections in the financial reports and information on
iXBRL website from 2023Q1 to 2023Q4, please go to “financial reports
correction inquiry” section on MOPS for more details.
8.Amounts/ contents/ number of page after correction:
Correct consolidated financial reports from 2023Q1 to 2023Q4, independent
2024Q4 financial report, and the information on iXBRL website. Due to the
large number of corrections in the financial reports and information on
iXBRL website from 2023Q1 to 2023Q4, please go to “financial reports
correction inquiry” section on MOPS for more details.
9.Countermeasures:Upload the corrected financial reports and iXBRL to MOPS.
10.Any other matters that need to be specified: N/A